BridgeBio Oncology Therapeutics (BBOT) Earnings Analysis
BridgeBio Oncology Therapeutics (BBOT) next reports earnings on 2026-08-11, consensus EPS -0.54265 USD. Last quarter (2026-06-04) it missed with EPS -0.52611 USD vs -0.51197 USD est (-2.8%). It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E -1.56.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BBOT next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.54265 USD |
| Revenue estimate | n/a |
BBOT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-06-04 | -0.52611 USD | -0.51197 USD | -2.8% | Miss |
| 2025-11-12 | -1.03 USD | -0.41 USD | -151.2% | Miss |
| 2025-08-01 | 0.03906 USD | n/a | n/a | n/a |
| 2025-05-15 | -0.02073 USD | n/a | n/a | n/a |
| 2025-03-11 | 0.1174 USD | n/a | n/a | n/a |
| 2024-11-14 | 0.09925 USD | n/a | n/a | n/a |
| 2024-08-14 | 0.09411 USD | n/a | n/a | n/a |
Beat rate: 0/2 (0%) over reported quarters with consensus data.
BBOT valuation and analyst view
| Trailing P/E | -1.56 |
|---|---|
| Trailing EPS | -4.9477 USD |
| Price / book | 0.74 |
| Dividend yield | 0.00% |
| Market cap | 0.72B |
| Analyst consensus | Buy (3 buy / 0 hold / 0 sell) |
| Avg price target | 23 USD |
Related research pages
Frequently asked questions
When is BridgeBio Oncology Therapeutics (BBOT)'s next earnings date?
BridgeBio Oncology Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.54265 USD.
Did BBOT beat earnings last quarter?
In its 2026-06-04 report, BBOT posted EPS of -0.52611 USD versus a -0.51197 USD estimate — a miss of 2.8%.
What is BBOT's earnings track record?
Over the last 2 reported quarters with consensus data, BBOT beat estimates 0 times (0%).
What is BBOT's current P/E ratio and EPS?
BBOT trades at a trailing P/E of -1.56 on trailing EPS of -4.947699895086736 USD.
What do analysts rate BBOT?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 23 USD.